CR11207A - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- CR11207A CR11207A CR11207A CR11207A CR11207A CR 11207 A CR11207 A CR 11207A CR 11207 A CR11207 A CR 11207A CR 11207 A CR11207 A CR 11207A CR 11207 A CR11207 A CR 11207A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- organic compounds
- alk
- meanings
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Abstract
Los compuestos de la formula I en forma libre o de sal o de solvato, en donde R1, R2 y R5 tiene los significados indicados en la memoria descriptiva, son utiles para el tratamiento de las enfermedades mediadas por el receptor de ALK-5 y/o ALK-4. Tambien se describen composiciones farmaceuticas que contienen los compuestos y procesos para la preparacion de estos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113214 | 2007-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11207A true CR11207A (es) | 2010-02-12 |
Family
ID=38694831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11207A CR11207A (es) | 2007-07-26 | 2010-01-08 | Compuestos organicos |
Country Status (22)
Country | Link |
---|---|
US (1) | US8143253B2 (es) |
EP (1) | EP2183027B1 (es) |
JP (1) | JP5090528B2 (es) |
KR (1) | KR101150581B1 (es) |
CN (1) | CN101765442B (es) |
AT (1) | ATE522249T1 (es) |
AU (1) | AU2008280135B2 (es) |
BR (1) | BRPI0813625A2 (es) |
CA (1) | CA2694261A1 (es) |
CL (1) | CL2008002184A1 (es) |
CO (1) | CO6290714A2 (es) |
CR (1) | CR11207A (es) |
EA (1) | EA201000123A1 (es) |
EC (1) | ECSP109898A (es) |
ES (1) | ES2375425T3 (es) |
MA (1) | MA31571B1 (es) |
PE (1) | PE20090506A1 (es) |
SV (1) | SV2010003463A (es) |
TN (1) | TN2010000040A1 (es) |
TW (1) | TW200911814A (es) |
WO (1) | WO2009013335A1 (es) |
ZA (1) | ZA201000079B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1932846T3 (pl) * | 2005-08-30 | 2011-05-31 | Sumitomo Chemical Co | Sposób wytwarzania związku zawierającego grupę chlorosulfonylową |
EP2277881A4 (en) * | 2008-04-18 | 2011-09-07 | Shionogi & Co | HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K |
CN103384670B (zh) * | 2010-07-28 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的咪唑并[1,2-b]哒嗪 |
WO2012088266A2 (en) * | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
SG195100A1 (en) * | 2011-07-01 | 2013-12-30 | Bayer Ip Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
CN104135859B (zh) | 2011-12-28 | 2017-06-27 | 全球血液疗法公司 | 取代的苯甲醛化合物及其用于增加组织氧合的方法 |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
ES2660051T3 (es) * | 2012-09-28 | 2018-03-20 | Vanderbilt University | Compuestos heterocíclicos condensados como inhibidores selectivos de BMP |
SG11201502527UA (en) * | 2012-10-05 | 2015-04-29 | Rigel Pharmaceuticals Inc | Gdf-8 inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
JP6463327B2 (ja) | 2013-03-15 | 2019-01-30 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
DK3102208T4 (da) | 2014-02-07 | 2024-08-26 | Global Blood Therapeutics Inc | Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd |
US10233170B2 (en) | 2014-04-08 | 2019-03-19 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN107438607B (zh) | 2015-02-20 | 2021-02-05 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
EP3383392A1 (en) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
CN106478516A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种5‑氯哒嗪酮的合成方法 |
CN106478517A (zh) * | 2016-08-31 | 2017-03-08 | 安徽省鸿鑫生物科技有限公司 | 一种2‑甲基5‑氯哒嗪酮的合成方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN107805252A (zh) * | 2017-10-25 | 2018-03-16 | 上海道亦化工科技有限公司 | 一种基于咪唑并哒嗪的有机电致发光化合物及其用途和有机电致发光器件 |
DK3717471T3 (da) * | 2017-12-02 | 2022-01-31 | Galapagos Nv | Nye forbindelser og lægemiddelsammensætninger heraf til behandling af sygdomme |
TW201940481A (zh) | 2018-01-29 | 2019-10-16 | 美商維泰克斯製藥公司 | Gcn2抑制劑及其用途 |
EP3765460A1 (en) | 2018-03-14 | 2021-01-20 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
AU2019262195B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
SG11202106582YA (en) | 2018-12-20 | 2021-07-29 | Incyte Corp | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
CA3157428A1 (en) | 2019-12-19 | 2021-06-24 | Universite De Strasbourg | Sigma-1 receptor ligands and uses thereof |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
BR112022025191A2 (pt) * | 2020-06-12 | 2023-03-07 | Incyte Corp | Compostos de imidazopiridazina com atividade de inibidores de alk2 |
WO2022013311A1 (en) | 2020-07-15 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
KR20230051500A (ko) | 2020-07-15 | 2023-04-18 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
JP2023533850A (ja) | 2020-07-15 | 2023-08-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Alk5阻害剤としてのピリドオキサジンアミノ誘導体 |
US20240116948A1 (en) | 2020-12-23 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
AR127108A1 (es) | 2021-09-21 | 2023-12-20 | Chiesi Farm Spa | Derivados de amino piridazinilo como inhibidores de alk5 |
WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9707391A (pt) | 1996-02-07 | 1999-07-20 | Janssen Pharmaceutica Nv | Pirazolpirimidinas como antagonistas de receptor de crf |
ATE256128T1 (de) * | 1998-10-21 | 2003-12-15 | Takeda Chemical Industries Ltd | Kondensierte pyridazinderivate, verfahren zu ihrer herstellung und ihre anwendung |
GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
JP4564485B2 (ja) | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ[1,5−a]ピリミジン誘導体 |
DE602004006536T2 (de) * | 2003-12-31 | 2008-01-31 | Schering-Plough Ltd. | Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten |
AU2005301568B2 (en) * | 2004-11-08 | 2011-06-09 | Msd K.K. | Novel fused imidazole derivative |
PT1869049E (pt) | 2005-03-21 | 2009-05-26 | Lilly Co Eli | Compostos de imidazopiridazina |
US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
-
2008
- 2008-07-24 BR BRPI0813625-4A2A patent/BRPI0813625A2/pt not_active IP Right Cessation
- 2008-07-24 US US12/670,188 patent/US8143253B2/en not_active Expired - Fee Related
- 2008-07-24 CN CN200880100481.6A patent/CN101765442B/zh not_active Expired - Fee Related
- 2008-07-24 ES ES08775322T patent/ES2375425T3/es active Active
- 2008-07-24 JP JP2010517403A patent/JP5090528B2/ja not_active Expired - Fee Related
- 2008-07-24 CA CA2694261A patent/CA2694261A1/en not_active Abandoned
- 2008-07-24 PE PE2008001257A patent/PE20090506A1/es not_active Application Discontinuation
- 2008-07-24 KR KR1020107001656A patent/KR101150581B1/ko not_active IP Right Cessation
- 2008-07-24 AT AT08775322T patent/ATE522249T1/de not_active IP Right Cessation
- 2008-07-24 EA EA201000123A patent/EA201000123A1/ru unknown
- 2008-07-24 WO PCT/EP2008/059705 patent/WO2009013335A1/en active Application Filing
- 2008-07-24 AU AU2008280135A patent/AU2008280135B2/en not_active Ceased
- 2008-07-24 EP EP08775322A patent/EP2183027B1/en active Active
- 2008-07-25 TW TW097128501A patent/TW200911814A/zh unknown
- 2008-07-25 CL CL2008002184A patent/CL2008002184A1/es unknown
-
2010
- 2010-01-05 ZA ZA201000079A patent/ZA201000079B/xx unknown
- 2010-01-08 CR CR11207A patent/CR11207A/es not_active Application Discontinuation
- 2010-01-22 TN TNP2010000040A patent/TN2010000040A1/fr unknown
- 2010-01-22 MA MA32544A patent/MA31571B1/fr unknown
- 2010-01-25 EC EC2010009898A patent/ECSP109898A/es unknown
- 2010-01-25 CO CO10007036A patent/CO6290714A2/es not_active Application Discontinuation
- 2010-01-26 SV SV2010003463A patent/SV2010003463A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101765442B (zh) | 2014-09-17 |
ES2375425T3 (es) | 2012-02-29 |
US20100204235A1 (en) | 2010-08-12 |
EP2183027A1 (en) | 2010-05-12 |
WO2009013335A1 (en) | 2009-01-29 |
ATE522249T1 (de) | 2011-09-15 |
CO6290714A2 (es) | 2011-06-20 |
CN101765442A (zh) | 2010-06-30 |
AU2008280135B2 (en) | 2012-02-23 |
US8143253B2 (en) | 2012-03-27 |
EA201000123A1 (ru) | 2010-08-30 |
BRPI0813625A2 (pt) | 2014-12-23 |
PE20090506A1 (es) | 2009-05-28 |
EP2183027B1 (en) | 2011-08-31 |
KR101150581B1 (ko) | 2012-06-11 |
CL2008002184A1 (es) | 2009-05-08 |
CA2694261A1 (en) | 2009-01-29 |
KR20100034028A (ko) | 2010-03-31 |
AU2008280135A1 (en) | 2009-01-29 |
ECSP109898A (es) | 2010-02-26 |
JP5090528B2 (ja) | 2012-12-05 |
ZA201000079B (en) | 2010-09-29 |
SV2010003463A (es) | 2010-04-13 |
TN2010000040A1 (en) | 2011-09-26 |
MA31571B1 (fr) | 2010-08-02 |
JP2010534633A (ja) | 2010-11-11 |
TW200911814A (en) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2010003463A (es) | Compuestos organicos | |
TN2010000167A1 (en) | Organic compounds | |
TN2010000305A1 (en) | Pyrrolopyrimidines and pyrrolopyridines | |
EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
EA201100299A1 (ru) | Органические соединения | |
TW200637863A (en) | Organic compounds | |
BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
MX339899B (es) | Compuestos de triazolopiridina como inhibidores de pim cinasa. | |
MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
BRPI0519292A2 (pt) | compostos orgÂnicos | |
TW200630366A (en) | Organic compounds | |
PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
WO2013040227A3 (en) | Therapeutic compounds | |
WO2008104473A3 (en) | Pyrazolopyriidine derivatives and their use as kinase inhibitors | |
WO2007068473A3 (en) | Organic compounds | |
GB0602951D0 (en) | Organic Compounds | |
MX2010002007A (es) | Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace. | |
GB0428416D0 (en) | Organic compounds | |
TW200800993A (en) | Organic compounds | |
MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. | |
BRPI0507283A (pt) | compostos orgánicos | |
CU20100011A7 (es) | Compuestos orgánicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |